Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.